title: New incretin hormonal therapies in humans relevant to diabetic cats.
abstract: Incretins (gastric inhibitory polypeptide and glucagon-like peptide 1 [GLP-1]) are hormones released from the gastrointestinal tract during food intake that potentiate insulin secretion. Native GLP-1 is quickly degraded by the enzyme dipeptidylpeptidase-4 (DPP-4), which has led to the development of GLP-1 agonists with resistance to degradation and to inhibitors of DPP-4 activity as therapeutic agents in humans with type 2 diabetes. In healthy cats, GLP-1 agonists and DPP-4 inhibitors have produced a substantial increase in insulin secretion. Although results of clinical studies are not yet available, incretin-based therapy promises to become an important new research area in feline diabetes.
authors.affiliation: Vetsuisse Faculty, Department of Small Animals, Clinic for Small Animal Internal Medicine, Zurich, Switzerland. creusch@vetclinics.uzh.ch
authors.forename: Claudia E
authors.initials: CE
authors.lastname: Reusch
authors.forename: Isabelle
authors.initials: I
authors.lastname: Padrutt
mesh_terms: D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000662:veterinary*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005749:Gastric Inhibitory Polypeptide / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000627:therapeutic use; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D016896:Treatment Outcome
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D004791:Enzyme Inhibitors; D054795:Incretins; D007328:Insulin; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4